In a report issued on January 24, Danielle Antalffy from Leerink Partners maintained a Buy rating on Inari Medical (NARI – Research Report), with a price target of $85.00. The company’s shares closed last Thursday at $77.58.
According to TipRanks.com, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Inari Medical with a $112.50 average price target, representing a 48.7% upside. In a report issued on January 10, BTIG also maintained a Buy rating on the stock with a $140.00 price target.
Based on Inari Medical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $72.92 million and GAAP net loss of $2.8 million. In comparison, last year the company earned revenue of $38.72 million and had a net profit of $6.5 million.
Based on the recent corporate insider activity of 106 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NARI in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from venous diseases. Its product portfolio includes ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTreiver product is used for the treatment of pulmonary embolism. Geographically, the company has its presence across the United States.
Read More on NARI:
- Robert W. Baird Maintains Their Buy Rating on Textron (TXT)
- Albany International (AIN) Gets a Hold Rating from Robert W. Baird
- Robert W. Baird Believes Raytheon Technologies (RTX) Still Has Room to Grow
- Leerink Partners Thinks Nevro Crop’s Stock is Going to Recover
- Leerink Partners Believes Baxter International (BAX) Still Has Room to Grow